Page last updated: 2024-10-30

mazindol and Depressive Disorder, Major

mazindol has been researched along with Depressive Disorder, Major in 1 studies

Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.

Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Sekiguchi, H1
Pavey, G1
Dean, B1

Other Studies

1 other study available for mazindol and Depressive Disorder, Major

ArticleYear
Altered levels of dopamine transporter in the frontal pole and the striatum in mood disorders: A postmortem study.
    Journal of affective disorders, 2023, 01-01, Volume: 320

    Topics: Depressive Disorder, Major; Dopamine; Dopamine Plasma Membrane Transport Proteins; Humans; Mazindol;

2023